Kert D. Sabbath

3.4k total citations · 1 hit paper
26 papers, 2.7k citations indexed

About

Kert D. Sabbath is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Kert D. Sabbath has authored 26 papers receiving a total of 2.7k indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Oncology, 9 papers in Cancer Research and 6 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Kert D. Sabbath's work include Colorectal Cancer Treatments and Studies (6 papers), Cancer Treatment and Pharmacology (6 papers) and Lung Cancer Research Studies (5 papers). Kert D. Sabbath is often cited by papers focused on Colorectal Cancer Treatments and Studies (6 papers), Cancer Treatment and Pharmacology (6 papers) and Lung Cancer Research Studies (5 papers). Kert D. Sabbath collaborates with scholars based in United States, Netherlands and Japan. Kert D. Sabbath's co-authors include Bruce Saidman, Steven J. Cohen, Cornelis J.A. Punt, Nicholas Iannotti, Neal J. Meropol, Michael Craig Miller, Edith P. Mitchell, Joel Picus, Gerald V. Doyle and H. Tissing and has published in prestigious journals such as Journal of Clinical Investigation, Journal of Clinical Oncology and Cancer.

In The Last Decade

Kert D. Sabbath

25 papers receiving 2.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Relationship of Circulating Tumor Cells to Tumor Response, Progression-Free Survival, and Overall Survival in Patients With Metastatic Colorectal Cancer

2008 1.5k citations Steven J. Cohen, Cornelis J.A. Punt et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Kert D. Sabbath United States	12	1.9k	1.2k	544	541	456	26	2.7k
Jaco Kraan Netherlands	36	1.6k 0.8×	1.2k 1.0×	1.1k 2.0×	832 1.5×	306 0.7×	112	3.5k
J. M. Nesland Norway	31	1.5k 0.8×	945 0.8×	1.1k 2.1×	780 1.4×	306 0.7×	59	3.0k
Bruce Saidman United States	11	1.8k 0.9×	1.2k 1.0×	354 0.7×	508 0.9×	440 1.0×	14	2.2k
Kelly Bethel United States	27	1.2k 0.6×	939 0.8×	553 1.0×	430 0.8×	489 1.1×	62	2.3k
Maria Perraki Greece	24	2.0k 1.0×	1.5k 1.3×	492 0.9×	682 1.3×	229 0.5×	49	2.4k
H. Tissing Netherlands	7	3.1k 1.6×	2.1k 1.8×	632 1.2×	1.4k 2.6×	795 1.7×	10	4.0k
Glen Clack United Kingdom	22	2.6k 1.4×	1.3k 1.0×	798 1.5×	841 1.6×	364 0.8×	61	3.3k
H. Nekarda Germany	29	1.6k 0.8×	586 0.5×	1.1k 2.0×	925 1.7×	233 0.5×	48	3.4k
Christian Schindlbeck Germany	30	3.0k 1.5×	2.1k 1.8×	918 1.7×	912 1.7×	585 1.3×	83	4.0k
Ricardo H. Álvarez United States	28	1.7k 0.9×	1.1k 0.9×	824 1.5×	558 1.0×	112 0.2×	75	2.7k

Countries citing papers authored by Kert D. Sabbath

Since Specialization

Citations

This map shows the geographic impact of Kert D. Sabbath's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kert D. Sabbath with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kert D. Sabbath more than expected).

Fields of papers citing papers by Kert D. Sabbath

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kert D. Sabbath. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kert D. Sabbath. The network helps show where Kert D. Sabbath may publish in the future.

Co-authorship network of co-authors of Kert D. Sabbath

This figure shows the co-authorship network connecting the top 25 collaborators of Kert D. Sabbath. A scholar is included among the top collaborators of Kert D. Sabbath based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kert D. Sabbath. Kert D. Sabbath is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Li, Fangyong, Terri L. Parker, Noffar Bar, et al.. (2024). Open-label, single-arm phase Ib/II study of immune combination therapy with elotuzumab and belantamab mafodotin in patients with relapsed refractory multiple myeloma.. Journal of Clinical Oncology. 42(16_suppl). 7559–7559. 1 indexed citations

Chiang, Anne C., Scott Gettinger, Sarah B. Goldberg, et al.. (2023). Molecular predictors and immunomodulatory role of dual checkpoint inhibitor blockade using ipilimumab/nivolumab in patients with extensive stage small cell lung cancer.. Journal of Clinical Oncology. 41(16_suppl). 8597–8597. 1 indexed citations

Chiang, Anne C., Matthew Austin, Tyler F. Stewart, et al.. (2022). A pilot study of ipilimumab and nivolumab in recurrent extensive-stage small cell lung cancer after platinum-based chemotherapy.. Journal of Clinical Oncology. 40(16_suppl). 8583–8583. 1 indexed citations

Cecchini, Michael, Jeremy Kortmansky, Can Cui, et al.. (2020). A phase 1b expansion study of TAS‐102 with oxaliplatin for refractory metastatic colorectal cancer. Cancer. 127(9). 1417–1424. 7 indexed citations

Cecchini, Michael, Jeremy Kortmansky, Jill Lacy, et al.. (2019). A phase I study of TAS-102 in combination with oxaliplatin (TAS-OX) for refractory metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology. 37(4_suppl). 630–630. 5 indexed citations

Foldi, Julia, Sarah S. Mougalian, Andrea Silber, et al.. (2018). Single-arm, neoadjuvant, phase II trial of pertuzumab and trastuzumab administered concomitantly with weekly paclitaxel followed by 5-fluoruracil, epirubicin, and cyclophosphamide (FEC) for stage I–III HER2-positive breast cancer. Breast Cancer Research and Treatment. 169(2). 333–340. 14 indexed citations

Zhu, Quing, Susan Tannenbaum, Scott H. Kurtzman, et al.. (2018). Identifying an early treatment window for predicting breast cancer response to neoadjuvant chemotherapy using immunohistopathology and hemoglobin parameters. Breast Cancer Research. 20(1). 56–56. 18 indexed citations

Abu‐Khalaf, Maysa, Sarah S. Mougalian, Tara Sanft, et al.. (2015). A phase II trial of neoadjuvant aromatase inhibitor therapy and the mTOR inhibitor everolimus in postmenopausal women with hormone receptor positive/HER2 negative breast cancer and a low/intermediate risk Oncotype Dx Recurrence Score (≤ 25).. Journal of Clinical Oncology. 1 indexed citations

Aggarwal, Charu, Neal J. Meropol, Cornelis J.A. Punt, et al.. (2012). Relationship among circulating tumor cells, CEA and overall survival in patients with metastatic colorectal cancer. Annals of Oncology. 24(2). 420–428. 143 indexed citations

10.

Cohen, Steven J., Cornelis J.A. Punt, Nicholas Iannotti, et al.. (2009). Prognostic significance of circulating tumor cells in patients with metastatic colorectal cancer. Annals of Oncology. 20(7). 1223–1229. 418 indexed citations

11.

Cohen, Steven J., Cornelis J.A. Punt, Nicholas Iannotti, et al.. (2008). Relationship of Circulating Tumor Cells to Tumor Response, Progression-Free Survival, and Overall Survival in Patients With Metastatic Colorectal Cancer. Journal of Clinical Oncology. 26(19). 3213–3221. 1473 indexed citations breakdown →

12.

Sabbath, Kert D. & Lee S. Schwartzberg. (2008). Circulating tumor cells: ready for prime time. Community Oncology. 5(9). 516–524. 1 indexed citations

13.

Meropol, Neal J., Steven J. Cohen, Nicholas Iannotti, et al.. (2007). Circulating tumor cells (CTC) predict progression free (PFS) and overall survival (OS) in patients with metastatic colorectal cancer. Journal of Clinical Oncology. 25(18_suppl). 4010–4010. 18 indexed citations

14.

Riely, Gregory J., Shirish M. Gadgeel, Ivan Rothman, et al.. (2006). A phase 2 study of TZT-1027, administered weekly to patients with advanced non-small cell lung cancer following treatment with platinum-based chemotherapy. Lung Cancer. 55(2). 181–185. 44 indexed citations

15.

Percarpio, Bernard, et al.. (1992). Combined modality preoperative therapy for unresectable rectal cancer.. PubMed. 56(1). 7–9. 5 indexed citations

16.

Herrmann, F., James D. Griffin, Kert D. Sabbath, et al.. (1988). Identification and purification of human erythroid progenitor cells by monoclonal antibody to the transferrin receptor (T� 67). Annals of Hematology. 56(4). 179–183. 3 indexed citations

17.

Posner, Marshall R., J. Belliveau, Alan B. Weitberg, et al.. (1987). Continuous-infusion cisplatin and bolus 5-fluorouracil in colorectal carcinoma.. PubMed. 71(10). 975–7. 8 indexed citations

18.

Sabbath, Kert D. & James D. Griffin. (1985). Clonogenic cells in acute myeloblasts leukaemia. Scandinavian Journal of Haematology. 35(3). 251–256. 9 indexed citations

19.

Sabbath, Kert D., et al.. (1985). Heterogeneity of clonogenic cells in acute myeloblastic leukemia.. Journal of Clinical Investigation. 75(2). 746–753. 150 indexed citations

20.

Griffin, James D., et al.. (1984). A monoclonal antibody reactive with normal and leukemic human myeloid progenitor cells. Leukemia Research. 8(4). 521–534. 347 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact